[Lower urinary tract symptoms secondary to benign prostatic hyperplasia in 2017: update from the 32nd annual congress of European association of urology].
This review article summarizes new data on mono- and combination therapy for male urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). A special attention is paid to the reports made at the 32nd Annual EAU Congress and published in the congress proceedings. The article outlines new data on the epidemiology of LUTS secondary to BPH, recent changes in the pathogenesis of LUTS, provides a critical analysis of the latest publications on -blockers, 5-reductase inhibitors, antimuscarinics and phosphodiesterase type 5 inhibitors in pharmacological management of LUTS. The authors analyze recent data on the effectiveness of surgical methods for treating BPH.